CROSSJECT

CROSSJECT is an emerging specialty pharmaceutical company developing medications dedicated to emergency situations, leveraging its proprietary platform built around the award-winning ZENEO® needle-free auto-injector. The company is in advanced regulatory development for ZEPIZURE®, an emergency treatment for managing epileptic seizures, for which CROSSJECT has secured a $60 million contract* with the U.S. Biomedical Advanced Research and Development Authority (BARDA)... CROSSJECT is a specialty pharmaceutical company revolutionizing the delivery of rapid-acting emergency medications through ZENEO®, its safe and reliable needle-free auto-injector designed for critical situations... Crossject is revolutionizing the administration of well-established treatments with its needle-free auto-injector ZENEO®.

Primary location: Dijon France